Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trehalose in Alzheimer's Disease
NCT04663854Phase 1Unknown
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Modality
- Drug Delivery Systems, DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial in Alzheimer's disease (AD) comparing Trehalose with Placebo (2 arms). Primary endpoints: Changes of Mini-Mental State Exam at 12 weeks and Changes in Clinical Dementia Rating Scale at 12 weeks. Status: unknown.
02
Drugs
trehalose
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04663854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04663854.